Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00755703 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.
A Phase 1 study, sponsored by Altimmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00755703 is a Phase 1 study that has completed, run by Altimmune. The registered enrollment target is 48 participants.
The verdict
NCT00755703, a Phase 1 study, has completed, sponsored by Altimmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to test the recombinant vaccine for safety and immunogenicity in healthy adults volunteers. Single dose, intranasally administered vaccine using an adenovirus-recombinant vector has provided a safe route for inducing protection in animals against pandemic influenza in preclinical studies. The vaccine is non-replicating, tissue culture based and designed for intranasal delivery.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Pandemic Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00755703
The ClinicalTrials.gov registry entry for NCT00755703 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altimmune, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00755703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00755703 about?
NCT00755703 is a clinical study titled "Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.". The purpose of this study is to test the recombinant vaccine for safety and immunogenicity in healthy adults volunteers. Single dose, intranasally administered vaccine using an adenovirus-recombinant vector has provided a safe route for inducing protection in animals against pandemic influenza in pr...
What is the current status of trial NCT00755703?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2008-10. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00755703?
The interventions under investigation include: Placebo (BIOLOGICAL), Pandemic Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00755703?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.